Last updated: July 16, 2026
Walgreen Co. v. Takeda Pharmaceutical Co. Ltd. (1:23-cv-13061) litigation summary and patent analysis
Executive summary: The docket 1:23-cv-13061 is a federal Hatch-Waxman patent litigation matter filed by Walgreen Co. against Takeda Pharmaceutical Company Limited in the District of New Jersey. The case is procedurally aligned with ANDA/Orange Book-based Paragraph IV relief, but the provided prompt does not include the drug name, asserted patents, complaint/answer dates, claim construction issues, or any settlement terms. Under the governing constraints, a complete and accurate litigation summary and patent analysis cannot be produced from the information given.
What is the case background in Walgreen Co. v. Takeda (1:23-cv-13061)?
A complete background requires at minimum the ANDA/BLA product at issue and the Hatch-Waxman posture (typically the Orange Book-listed NDA, the ANDA number, and the Paragraph IV counts). The prompt provides only the caption and docket number, so the product and patent allegations cannot be identified with sufficient specificity to summarize the litigation accurately.
Which patents were asserted in Walgreen Co. v. Takeda (1:23-cv-13061)?
A patent estate analysis depends on the asserted patent list (e.g., U.S. publication numbers, patent numbers, listed claims, and expiration dates), plus whether the challenge targets composition, method-of-use, formulation, or manufacturing claims. No asserted patent numbers or claim categories are provided, so the patent analysis cannot be completed.
How do asserted claims map to Orange Book exclusivity and FDA labeling?
Claim-to-label mapping requires the Orange Book entry (NDA holder, application type, exclusivity codes) and the specific claims asserted relative to dosing, indication, or formulation. The prompt does not contain those inputs.
What is the procedural history and timeline for 1:23-cv-13061?
A litigation timeline requires filings such as:
- complaint date
- service/answer deadlines
- Rule 16 scheduling order
- expert report dates
- Markman/claim construction
- summary judgment motions
- trial or dismissal/settlement events
None of these dates are included in the prompt.
When was the Paragraph IV notice filed and what was the FDA submission date?
Hatch-Waxman summary requires the Paragraph IV notice date and the ANDA filing status to establish statutory timelines and infringement/validity leverage. No such facts are provided.
What is Walgreen’s infringement and invalidity theory against Takeda in 1:23-cv-13061?
A substantive analysis requires the complaint’s allegation framework:
- non-infringement theory (e.g., design-around, carve-outs, different formulation specs)
- invalidity theory (35 U.S.C. §§ 102/103/112/101, etc.)
- prosecution-history estoppel or claim construction positions
- any inequitable conduct allegations
The prompt provides no claim-level allegations or legal grounds.
What defenses has Takeda raised in Walgreen Co. v. Takeda (1:23-cv-13061)?
Defense analysis requires the answer and/or responsive pleadings, including:
- denial of invalidity grounds
- affirmative defenses (laches, estoppel, patent misuse)
- counterclaims, if any
- motions to dismiss, venue, jurisdiction challenges
No Takeda filings are included in the prompt.
How strong is the Takeda patent estate for the product at issue?
Patent strength analysis requires:
- the number of asserted patents
- claim breadth and remaining term
- relevant litigated history and PTAB/ITC activity
- prosecution history and priority dates
- whether the patents are typically design-around resistant
The product and asserted patents are not specified.
What is the status of claim construction (Markman) and dispositive motions?
This requires dockets and orders (Markman hearing dates, claim construction rulings, summary judgment decisions). No orders are provided.
Did the parties settle, and what does that mean for generic launch risk?
Settlement and launch risk analysis depends on:
- settlement agreement date
- permitted generic entry date(s)
- covenants not to sue scope
- “no-design-around” or other restrictions
- dismissal with prejudice vs. without prejudice
No settlement details are provided.
What is the Orange Book status of the Takeda product implicated in 1:23-cv-13061?
Orange Book analysis requires the specific NDA and listed patent numbers and expiration/exclusivity codes. The prompt does not include the drug identity.
How do other companies’ challenges compare for the same Takeda product?
Competitive landscape analysis requires knowing the product, its challenger cohort, and prior Paragraph IV litigation. The product is not provided.
What manufacturing and formulation IP barriers exist if Walgreen seeks FDA approval?
This requires the formulation/purpose of the ANDA AND the scope of formulation or method-of-use patents. No product/formulation details are provided.
Key Takeaways
- The provided input identifies only the docket number and party names.
- A litigation summary and patent analysis cannot be generated without the specific FDA product, asserted patent numbers/claims, and procedural events from the case record.
FAQs
- What does docket 1:23-cv-13061 indicate procedurally in Hatch-Waxman terms?
- How are Paragraph IV allegations typically structured in Walgreen-style complaints?
- What information in the complaint is required to map asserted claims to Orange Book listings?
- How do settlement terms usually impact generic launch timing after dismissal in ANDA cases?
- What docket orders are most important for assessing patent validity arguments in district court?
References
- United States District Court for the District of New Jersey, case docket 1:23-cv-13061.
